Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor therapy (M.D. Anderson Cancer Center)

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NameEngineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor therapy (M.D. Anderson Cancer Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionInterleukin-13 receptor subunit alpha-1 modulatorsNatural killer cell replacementsEpidermal growth factor receptor variant III modulators
TargetsInterleukin-13 receptor subunit alpha-1Epidermal growth factor receptor variant III
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A